Technical Analysis for BDSI - BioDelivery Sciences International, Inc.

Grade Last Price % Change Price Change
grade A 4.32 0.93% 0.04
BDSI closed up 0.93 percent on Friday, January 18, 2019, on 70 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BDSI trend table...

Date Alert Name Type % Chg
Jan 18 New 52 Week Closing High Bullish 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 18 Up 5 Days in a Row Strength 0.00%
Jan 17 New 52 Week Closing High Bullish 0.93%
Jan 17 Pocket Pivot Bullish Swing Setup 0.93%
Jan 17 New 52 Week High Strength 0.93%

Older signals for BDSI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapeutics in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) drug delivery technology that consists of a small, bi-layered erodible polymer film for application to the buccal mucosa in the development of its products. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer; BEMA Buprenorphine that is in Phase III trial for the treatment of moderate to severe chronic pain in a mixed opioid naïve and opioid experienced population; BEMA Buprenorphine/Naloxone, which is in development stage for the treatment of opioid dependence; and BEMA Granisetron for the prevention of nausea and vomiting associated with cancer therapies. The company has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Is BDSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.38
52 Week Low 1.7
Average Volume 648,194
200-Day Moving Average 2.9793
50-Day Moving Average 3.6582
20-Day Moving Average 3.709
10-Day Moving Average 4.101
Average True Range 0.211
ADX 28.42
+DI 26.8987
-DI 12.6333
Chandelier Exit (Long, 3 ATRs ) 3.747
Chandelier Exit (Short, 3 ATRs ) 3.433
Upper Bollinger Band 4.6696
Lower Bollinger Band 2.7484
Percent B (%b) 0.82
BandWidth 51.798328
MACD Line 0.2116
MACD Signal Line 0.144
MACD Histogram 0.0676
Fundamentals Value
Market Cap 239.65 Million
Num Shares 55.5 Million
EPS 0.03
Price-to-Earnings (P/E) Ratio 144.00
Price-to-Sales 3.69
Price-to-Book 6.22
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.58
Resistance 3 (R3) 4.56 4.46 4.53
Resistance 2 (R2) 4.46 4.40 4.47 4.52
Resistance 1 (R1) 4.39 4.35 4.43 4.41 4.50
Pivot Point 4.29 4.29 4.31 4.30 4.29
Support 1 (S1) 4.22 4.23 4.26 4.24 4.14
Support 2 (S2) 4.12 4.18 4.13 4.12
Support 3 (S3) 4.05 4.12 4.11
Support 4 (S4) 4.07